We found that CD106-positive cells, a class of hematopoietic stem cell in Lineage (-), c-kit (+) and Sca-1 (+) (LSK) cells, are the culprits that underlie the pathogenesis of DN, and thus constitute a novel therapeutic target for the treatment of this highly prevalent diabetic complication. Here, VCAM1 is linked to liver dysplastic nodule.